A solo drug launch is a testing time for a small company, made even tougher by the pandemic.
The relatively low-key asset might at least partly be responsible for Biocryst shares more than doubling since the start of December.
The smaller company believes that its complement C3 inhibitor could make Soliris and Ultomiris redundant in PNH.
Important data releases are on the cards for Rhythm, Wave and Supernus, among others.
December promises big US decisions for Novartis, Astrazeneca and Fibrogen, as well as the FDA's first Covid-19 vaccine reviews.